It is a prospective, non-interventional, open-label study, in order to observe the safety and response in FLT3-ITD mutation positive AML patients who receiving sorafenib as induction, consolidation, salvage, maintenance or alleviative treatment. The duration of the study from June 2014 through May 2019, with the recruitment duration from June 2014 to May 2017. The inclusion criteria is: 1. Definitely diagnosed as AML 2. FLT3-ITD mutation has been confirmed 3. Accepting the prescription of sorafenib
Study Type
OBSERVATIONAL
Enrollment
100
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
RECRUITINGOverall Response Rate
Time frame: up to 2 years
Progress-Free Survival
Time frame: up to 2 years
Overall Survival
Time frame: up to 2 years
Leukemia-Free Survival
Time frame: up to 2 years
Median time to the onset of sorafenib resistance
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.